May 21, 2021
May 21, 2021 – The U.S. FDA has granted accelerated approval for RybrevantTM (amivantamab-vmjw),
manufactured by Janssen, to treat adults who have locally advanced
- Have any questions?
- +1-888-INTL-SOS
- support@globalreachhealth.com
Pharmacy Benefits Management
May 20, 2021
May 20, 2021 – The U.S. FDA has expanded emergency use authorization (EUA) for the Pfizer/BioNTech
COVID-19 vaccine to include prevention of COVID-19 in individuals 12-15 years of age
May 20, 2021
May 20, 2021 – The U.S. FDA has approved an expanded indication for Kedrab® [rabies immune globulin
(human)] solution for wound infiltration and intramuscular
May 20, 2021
May 20, 2021 – The U.S. FDA has approved a new indication for Opdivo® (nivolumab), manufactured by
Bristol Myers Squibb
May 14, 2021
May 14, 2021 – The U.S. FDA has approved EmpaveliTM (pegcetacoplan), manufactured by Apellis
Pharmaceuticals, to treat adults diagnosed with paroxysmal nocturnal hemoglobinuria (PNH)
May 13, 2021
May 13, 2021 – The U.S. FDA has approved Heron Therapeutics’ ZynrelefTM (bupivacaine/meloxicam)
extended-release solution for soft tissue or periarticular instillation to produce postsurgical
May 7, 2021
May 7, 2021 - As your Prescription Benefit Facilitator, Global Reach Health is committed to creating value by providing the highest quality service, innovative clinical solutions, and valuable trend management strategies.
May 7, 2021
May 7, 2021 – NovoNordisk has voluntarily recalled 1,468 samples of the following insulin products:
Levemir®, Tresiba®, Fiasp®, Novolog®, and Xultophy®. The affected samples were stored